A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of the Selective Met Inhibitor JNJ-38877605 in Subjects With Advanced or Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 May 2015
At a glance
- Drugs JNJ 38877605 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 18 Oct 2011 Actual initiation date changed from Mar 2008 to Feb 2008 as reported by ClinicalTrials.gov.
- 18 Oct 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 17 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.